Literature DB >> 15792800

Selection for TRAIL resistance results in melanoma cells with high proliferative potential.

Jing Jing Wu1, Xu Dong Zhang, Susan Gillespie, Peter Hersey.   

Abstract

To better understand the outcome of the interaction between TNF-related apoptosis-inducing factor (TRAIL) and tumor cells, we studied TRAIL-resistant melanoma cells resulting from prolonged exposure to TRAIL and found that they had higher proliferative activity than the parental cells both in vitro and in vivo. This was associated with reduced p53 and p21 expression and increased activation of Erk1/2 and Akt. Accelerated proliferation was not due to TRAIL-mediated signaling but appeared to be the result of selection of previously existing, characteristically distinct cells. Moreover, responses of p53 to stimulation in the TRAIL-resistant cells appeared to be impaired.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15792800     DOI: 10.1016/j.febslet.2005.02.041

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

Review 1.  Melanocyte receptors: clinical implications and therapeutic relevance.

Authors:  J Andrew Carlson; Gerald P Linette; Andrew Aplin; Bernard Ng; Andrzej Slominski
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

2.  Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

Authors:  Xue Wei Meng; Michael P Heldebrant; Karen S Flatten; David A Loegering; Haiming Dai; Paula A Schneider; Timothy S Gomez; Kevin L Peterson; Sergey A Trushin; Allan D Hess; B Douglas Smith; Judith E Karp; Daniel D Billadeau; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

3.  Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.

Authors:  Mary M McCarthy; Kyle A DiVito; Mario Sznol; Daniela Kovacs; Ruth Halaban; Aaron J Berger; Keith T Flaherty; Robert L Camp; Rossitza Lazova; David L Rimm; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

4.  Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.

Authors:  Tanmoy Mondal; Gururaj N Shivange; Rachisan Gt Tihagam; Evan Lyerly; Michael Battista; Divpriya Talwar; Roxanna Mosavian; Karol Urbanek; Narmeen S Rashid; J Chuck Harrell; Paula D Bos; Edward B Stelow; M Sharon Stack; Sanchita Bhatnagar; Jogender Tushir-Singh
Journal:  EMBO Mol Med       Date:  2021-02-15       Impact factor: 12.137

5.  The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.

Authors:  Fei Yan; Na Shen; Jiuxia Pang; Julian R Molina; Ping Yang; Shujun Liu
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

6.  Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells.

Authors:  Jiawen Li; Qin Shen; Rui Peng; Rongyi Chen; Ping Jiang; Yanqiu Li; Li Zhang; Jingjing Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-08-17

7.  EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line.

Authors:  Qin Shen; Fen Tian; Ping Jiang; Yanqiu Li; Li Zhang; Jingjing Lu; Jiawen Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29

8.  2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2.

Authors:  Hao Liu; Chen Chen Jiang; Christopher J Lavis; Amanda Croft; Li Dong; Hsin-Yi Tseng; Fan Yang; Kwang Hong Tay; Peter Hersey; Xu Dong Zhang
Journal:  Mol Cancer       Date:  2009-12-14       Impact factor: 27.401

9.  Temozolomide induces senescence but not apoptosis in human melanoma cells.

Authors:  N M Mhaidat; X D Zhang; J Allen; K A Avery-Kiejda; R J Scott; P Hersey
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640

Review 10.  The Treg/Th17 paradigm in lung cancer.

Authors:  Min-Chao Duan; Xiao-Ning Zhong; Guang-Nan Liu; Jin-Ru Wei
Journal:  J Immunol Res       Date:  2014-04-29       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.